Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.6K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K
Drug Distribution: Overview01:11

Drug Distribution: Overview

656
Drug distribution within the body is a dynamic process involving the movement of a drug in two directions across various compartments: from the bloodstream into tissues (tissue uptake) and from tissues back into the bloodstream (tissue release or redistribution). This process is passive and primarily driven by two variables: the concentration gradient between the bloodstream and the extravascular tissues and the drug's ability to cross the cell membrane.
Initially, the free drug in the...
656
Drug Clearance: Overview01:06

Drug Clearance: Overview

353
Drug elimination refers to drug removal from the body, either through urine or bile, by the kidneys or liver, respectively. A pharmacokinetic parameter, drug clearance, measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the drug's concentration in plasma.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
353
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Targeting SARS-CoV-2 Non-Structural Proteins: A Blueprint for Next-Generation Small-Molecule Coronavirus Antivirals.

Pharmaceutics·2026
Same author

Targeting SARS-CoV-2 Structural and Accessory Proteins: Emerging Opportunities for Small-Molecule Coronavirus Antivirals.

Pharmaceutics·2026
Same author

Structural Studies of βTrCP Reveal Plasticity in Binding Modes of Consensus and Nonconsensus Degrons.

ACS chemical biology·2026
Same author

Activity-based chemoproteomic profiling reveals the active kinome of <i>Leishmania</i>.

Frontiers in pharmacology·2026
Same author

Tetrazole-containing naphthalene bis-sulfonamide Keap1-Nrf2 interaction inhibitors with unexpected binding modes.

Redox biology·2025
Same author

Structural basis for small molecule binding to the SARS-CoV-2 nsp10-nsp14 ExoN complex.

Nucleic acids research·2025

相关实验视频

Updated: Jan 7, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

5.4K

基于碎片的药物发现:图形综述

Dana F AlKharboush1,2, Frank Kozielski1, Geoffrey Wells1

  • 1UCL School of Pharmacy, University College London (UCL), London, WC1N 1AX, United Kingdom.

Current research in pharmacology and drug discovery
|December 31, 2025
PubMed
概括

基于碎片的药物发现 (FBDD) 识别了与标结合的小分子,将其优化为有效的药物. 这种成熟的战略在难以实现的目标上表现出色,加速了新疗法的开发.

关键词:
药物发现 药物发现在FBDD和FBDD之间.碎片选 碎片选 碎片选基于碎片的药物发现.基于碎片的发现.结构生物学是结构生物学.无法实现的目标是无法实现的目标.

更多相关视频

Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin
06:29

Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin

Published on: March 3, 2021

5.9K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.4K

相关实验视频

Last Updated: Jan 7, 2026

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

5.4K
Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin
06:29

Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin

Published on: March 3, 2021

5.9K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.4K

科学领域:

  • 药用化学 医学化学
  • 结构生物学 结构生物学
  • 药物发现 药物发现 药物发现

背景情况:

  • 基于碎片的药物发现 (FBDD) 是识别新药线索的强大策略.
  • 在传统查方法失败的情况下,它为挑战性或以前难以实现的目标提供了优势.
  • FBDD可以识别低分子量碎片 (<300 Da),这些碎片与生物标结合较弱.

研究的目的:

  • 为了说明现代的FBDD工作流程.
  • 突出 FBDD 中实验和计算方法的整合.
  • 展示加速药物发现周期的创新.

主要方法:

  • 使用敏感的生物物理技术 (NMR,X射线晶体学,SPR) 检测碎片-目标相互作用.
  • 通过成长,链接或合并策略,以结构为导向优化碎片命中.
  • 实验数据与计算方法的整合,包括AI/ML.

主要成果:

  • FBDD成功地从弱结合的碎片中产生强大的线索.
  • 图书馆设计和选平台的创新提高了发现效率.
  • 美国食品和药物管理局批准的药物 (Vemurafenib,Venetoclax) 的案例研究证明了FBDD的成功.

结论:

  • FBDD是一种成熟且有效的药物发现方法,尤其适用于具有挑战性的目标.
  • 人工智能/机器学习和先进技术的整合正在进一步加速FBDD.
  • FBDD继续发展,推动开发变革性药物的边界.